drugset / Trial / NCT05822440

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

NCT05822440

Phase 1 Completed 12 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to learn how Itraconazole affects the blood level of PF-07817883 in Healthy Adults. This study is seeking participants who are: * male and female aged 18 to 65 years old, * overtly healthy. This can be determined my medical evaluation, medical history, lab tests etc. This study will consist of 2 parts, Period 1 and Period 2. Period 1: participants will take PF-07817883 one time by mouth at the study clinic. Period 2: participants will take PF-07817883 one time by mouth at the study clinic. They will also take daily itraconazole by mouth for 7 days. Participants will stay at the study clinic for 2 weeks in total. The study doctors will collect blood and urine samples from everyone. The study doctors will check participants' reactions to the study medicine for safety measures. There is a follow-up call at 28 to 35 days from the last dose of PF-07817883. Itraconazole is an approved medicine. It is also a metabolism inhibitor. When taken with some medicines, it affects the actual level of these medicines in the body. This study will compare blood levels of PF-07817883 given with and without Itraconazole. This will help decide safety and right amount for PF-07817883 when given with metabolism inhibitors.

Timeline

Start
2023-04-13
Primary completion
2023-07-10
Completion
2023-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuzatrelvir Small molecule Oral
Subject Itraconazole Small molecule Oral

Indications

No indication recorded.